Abstract
BackgroundThe dynamics of B cell reconstitution in relapsing or refractory ANCA-associated vasculitides (AAV) treated with rituximab (RTX) followed by standard immunosuppressants are not clear. While in patients with rheumatoid arthritis...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
